Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Sep;18(3):421–430. doi: 10.1111/j.1365-2125.1984.tb02484.x

The influence of cimetidine on the pharmacokinetics of 5-fluorouracil.

V J Harvey, M L Slevin, M R Dilloway, P I Clark, A Johnston, A F Lant
PMCID: PMC1463647  PMID: 6487480

Abstract

The influence of cimetidine pretreatment on the pharmacokinetics of 5-fluorouracil (5FU) has been studied in 15 ambulant patients with carcinoma. Neither pretreatment with a single dose of cimetidine (400 mg) nor with daily treatment at 1000 mg for 1 week altered 5FU pharmacokinetics. Pretreatment with cimetidine for 4 weeks (1000 mg daily) led to increased peak plasma concentrations of 5FU and also area under the plasma concentration-time curve (AUC). The peak plasma concentration after oral 5FU was increased by 74% from 18.7 +/- 4.5 micrograms/ml (mean +/- s.e. mean) to 32.6 +/- 4.4 micrograms/ml (P less than 0.05) and AUC was increased by 72% from 528 +/- 133 micrograms/ml-1 min (mean +/- s.e. mean) to 911 +/- 152 micrograms ml-1 min (P less than 0.05). After intravenous 5FU, AUC was increased by 27% from 977 +/- 96 micrograms ml-1 min (mean +/- s.e. mean) to 1353 +/- 124 micrograms ml-1 min (P less than 0.01). Total body clearance for 5FU following intravenous administration was decreased by 28% from 987 +/- 116 ml/min (mean +/- s.e. mean) to 711 +/- 87 ml/min (P less than 0.01). The elimination half-life of 5FU was not altered by cimetidine. The basis of the interaction between 5FU and cimetidine is uncertain but probably a combination of inhibited drug metabolism and reduced liver blood flow. The therapeutic implications are considerable and additional care should be taken in patients receiving the two drugs concomitantly.

Full text

PDF
421

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ansfield F., Klotz J., Nealon T., Ramirez G., Minton J., Hill G., Wilson W., Davis H., Jr, Cornell G. A phase III study comparing the clinical utility of four regimens of 5-fluorouracil: a preliminary report. Cancer. 1977 Jan;39(1):34–40. doi: 10.1002/1097-0142(197701)39:1<34::aid-cncr2820390107>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  2. Cohen J. L., Irwin L. E., Marshall G. J., Darvey H., Bateman J. R. Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893). Cancer Chemother Rep. 1974 Sep-Oct;58(5 Pt 1):723–731. [PubMed] [Google Scholar]
  3. Collins J. M., Dedrick R. L., King F. G., Speyer J. L., Myers C. E. Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther. 1980 Aug;28(2):235–246. doi: 10.1038/clpt.1980.156. [DOI] [PubMed] [Google Scholar]
  4. Dorr R. T., Alberts D. S. Cimetidine enhancement of cyclophosphamide antitumour activity. Br J Cancer. 1982 Jan;45(1):35–43. doi: 10.1038/bjc.1982.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Feely J., Wilkinson G. R., McAllister C. B., Wood A. J. Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med. 1982 May;96(5):592–594. doi: 10.7326/0003-4819-96-5-592. [DOI] [PubMed] [Google Scholar]
  6. Feely J., Wilkinson G. R., Wood A. J. Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med. 1981 Mar 19;304(12):692–695. doi: 10.1056/NEJM198103193041202. [DOI] [PubMed] [Google Scholar]
  7. Feely J., Wood A. J. Effects of cimetidine on the elimination and actions of ethanol. JAMA. 1982 May 28;247(20):2819–2821. [PubMed] [Google Scholar]
  8. Finch R. E., Bending M. R., Lant A. F. Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients. Br J Clin Pharmacol. 1979 Jun;7(6):613–617. doi: 10.1111/j.1365-2125.1979.tb04651.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Finj C., Sadée W. Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography. Cancer Chemother Rep. 1975 Mar-Apr;59(2 Pt 1):279–286. [PubMed] [Google Scholar]
  10. Freston J. W. Cimetidine. I. Developments, pharmacology, and efficacy. Ann Intern Med. 1982 Oct;97(4):573–580. doi: 10.7326/0003-4819-97-4-573. [DOI] [PubMed] [Google Scholar]
  11. Heagerty A. M., Donovan M. A., Castleden C. M., Pohl J. F., Patel L., Hedges A. Influence of cimetidine on pharmacokinetics of propranolol. Br Med J (Clin Res Ed) 1981 Jun 13;282(6280):1917–1919. doi: 10.1136/bmj.282.6280.1917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Henry D. A., Macdonald I. A., Kitchingman G., Bell G. D., Langman M. J. Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism. Br Med J. 1980 Sep 20;281(6243):775–777. doi: 10.1136/bmj.281.6243.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jackson J. E., Powell J. R., Wandell M., Bentley J., Dorr R. Cimetidine decreases theophylline clearance. Am Rev Respir Dis. 1981 Jun;123(6):615–617. doi: 10.1164/arrd.1981.123.6.615. [DOI] [PubMed] [Google Scholar]
  14. Johnston A., Woollard R. C. STRIPE: an interactive computer program for the analysis of drug pharmacokinetics. J Pharmacol Methods. 1983 May;9(3):193–199. doi: 10.1016/0160-5402(83)90038-4. [DOI] [PubMed] [Google Scholar]
  15. Klotz U., Reimann I. Elevation of steady-state diazepam levels by cimetidine. Clin Pharmacol Ther. 1981 Oct;30(4):513–517. doi: 10.1038/clpt.1981.196. [DOI] [PubMed] [Google Scholar]
  16. Knodell R. G., Holtzman J. L., Crankshaw D. L., Steele N. M., Stanley L. N. Drug metabolism by rat and human hepatic microsomes in response to interaction with H2-receptor antagonists. Gastroenterology. 1982 Jan;82(1):84–88. [PubMed] [Google Scholar]
  17. McDermott B. J., Van den Berg H. W., Martin W. M., Murphy R. F. Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans. Br J Cancer. 1983 Nov;48(5):705–710. doi: 10.1038/bjc.1983.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Messiha F. S., Hughes M. J. Liver alcohol and aldehyde dehydrogenase: inhibition and potentiation by histamine agonists and antagonists. Clin Exp Pharmacol Physiol. 1979 May-Jun;6(3):281–292. doi: 10.1111/j.1440-1681.1979.tb01250.x. [DOI] [PubMed] [Google Scholar]
  19. Neuvonen P. J., Tokola R. A., Kaste M. Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol. 1981;21(3):215–220. doi: 10.1007/BF00627923. [DOI] [PubMed] [Google Scholar]
  20. Phillips T. A., Howell A., Grieve R. J., Welling P. G. Pharmacokinetics of oral and intravenous fluorouracil in humans. J Pharm Sci. 1980 Dec;69(12):1428–1431. doi: 10.1002/jps.2600691220. [DOI] [PubMed] [Google Scholar]
  21. Puurunen J., Sotaniemi E., Pelkonen O. Effect of cimetidine on microsomal drug metabolism in man. Eur J Clin Pharmacol. 1980 Aug;18(2):185–187. doi: 10.1007/BF00561588. [DOI] [PubMed] [Google Scholar]
  22. Reimann I. W., Klotz U., Siems B., Frölich J. Cimetidine increases steady state plasma levels of propranolol. Br J Clin Pharmacol. 1981 Dec;12(6):785–790. doi: 10.1111/j.1365-2125.1981.tb01307.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Reitberg D. P., Bernhard H., Schentag J. J. Alteration of theophylline clearance and half-life by cimetidine in normal volunteers. Ann Intern Med. 1981 Nov;95(5):582–585. doi: 10.7326/0003-4819-95-5-582. [DOI] [PubMed] [Google Scholar]
  24. Schwinghammer T. L. Drug interactions with cimetidine. Am J Hosp Pharm. 1981 Dec;38(12):1976–1978. [PubMed] [Google Scholar]
  25. Serlin M. J., Sibeon R. G., Mossman S., Breckenridge A. M., Williams J. R., Atwood J. L., Willoughby J. M. Cimetidine: interaction with oral anticoagulants in man. Lancet. 1979 Aug 18;2(8138):317–319. doi: 10.1016/s0140-6736(79)90340-4. [DOI] [PubMed] [Google Scholar]
  26. Somogyi A., Gugler R. Drug interactions with cimetidine. Clin Pharmacokinet. 1982 Jan-Feb;7(1):23–41. doi: 10.2165/00003088-198207010-00002. [DOI] [PubMed] [Google Scholar]
  27. Spahn H., Mutschler E., Kirch W., Ohnhaus E. E., Janisch H. D. Influence of ranitidine on plasma metoprolol and atenolol concentrations. Br Med J (Clin Res Ed) 1983 May 14;286(6377):1546–1547. doi: 10.1136/bmj.286.6377.1546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Speeg K. V., Jr, Patwardhan R. V., Avant G. R., Mitchell M. C., Schenker S. Inhibition of microsomal drug metabolism by histamine H2-receptor antagonists studied in vivo and in vitro in rodents. Gastroenterology. 1982 Jan;82(1):89–96. [PubMed] [Google Scholar]
  29. Stolinsky D. C., Pugh R. P., Bateman J. R. 5-Fluorouracil (NSC-19893) therapy for pancreatic carcinoma: comparison of oral and intravenous routes. Cancer Chemother Rep. 1975 Sep-Oct;59(5):1031–1033. [PubMed] [Google Scholar]
  30. Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES